enGene Therapeutics (ENGN) stock rose as Piper Sandler upgraded the company following updated mid-stage trial data for its lead asset, detalimogene. Read more here.
Detailed price information for Engene Therapeutics Inc (ENGN-Q) from The Globe and Mail including charting and trades.
Detailed price information for Engene Therapeutics Inc (ENGN-Q) from The Globe and Mail including charting and trades.
BOSTON & MONTREAL, September 08, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates.
BOSTON & MONTREAL, September 01, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:
This is the newest page. Registered accounts read further back.